about
Does belatacept improve outcomes for kidney transplant recipients? A systematic reviewUse of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathyRisk evaluation and mitigation strategy programs in solid organ transplantation: the promises of information technologyCutting Edge: CTLA-4Ig Inhibits Memory B Cell Responses and Promotes Allograft Survival in Sensitized Recipients.Belatacept and mediastinal histoplasmosis in a kidney transplant patient.Classification of Kidney Transplant Recipients Using a Combination of Estimated GFR and Albuminuria Reflects Risk.Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation.Infectious complications of immune modulatory agents.Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity.Should belatacept be the centrepiece of renal transplantation?Unintended Immunological Consequences of Biologic Therapy.T-cell immunity in myocardial inflammation: pathogenic role and therapeutic manipulation.Kidney function endpoints in kidney transplant trials: a struggle for power.Quality and consistency of outcome reporting in clinical trials of immunosuppression in renal transplantation.Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection.Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice.APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIR™) to Induce Antigen-Specific T Regulatory Type 1 Cells.Belatacept: a novel immunosuppressive agent for kidney transplant recipientsLong-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis
P2860
Q28084644-166BEEBB-84ED-4F72-BCAE-8591DD953FF0Q33411321-66F29EB7-9478-4387-BB80-A7ACADDBB1EDQ34235791-80D8C61B-189D-452C-9B9A-E997144E01D8Q36176992-68209B69-090A-4A27-91F5-5109F1A39649Q36835315-5579E172-DC06-474E-B51B-7F6EB10DCB08Q37371986-69143744-CEF0-48DE-82E9-8AB41495994BQ38078123-71CDA600-BFAA-49E2-8FA8-9536414DF578Q38144976-C3E79013-D914-4E7F-A8AB-14DB3F00CE34Q38400396-F04A922A-FE5F-4930-928E-72BBC48233E5Q38681685-A5492A96-C69E-441E-9CC3-A5D3D2619F0EQ38862002-D7432CB6-17C8-48C9-9FD8-4BD7DCABEBB6Q38871098-983B066F-106E-45B2-BCF1-56EA7A1B4C16Q38945115-46621BEE-FD2B-4D3B-821C-9066E491F217Q39201859-FB7B8DC0-E6AB-49F5-90C4-6BA4C26725FBQ39433845-EF2E040B-FDC8-4255-9D19-A64B02DB16ADQ39808031-FDC5C287-D5BA-4C55-B15D-FF1BFA214751Q42057719-44B4A1C6-A4DA-4598-8B04-C06F601FD606Q42362413-A4C19B86-C288-41D0-9E82-0AD2CF876AB8Q55260575-6908490B-2994-4D85-B00C-A352EC6F0433Q56897769-E443DA5E-045C-4247-B04C-065E36E80007Q57305845-2FC90A64-FF99-458C-AEFC-79339B20554E
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Summary of the US FDA approval of belatacept.
@en
Summary of the US FDA approval of belatacept.
@nl
type
label
Summary of the US FDA approval of belatacept.
@en
Summary of the US FDA approval of belatacept.
@nl
prefLabel
Summary of the US FDA approval of belatacept.
@en
Summary of the US FDA approval of belatacept.
@nl
P2093
P2860
P1476
Summary of the US FDA approval of belatacept.
@en
P2093
P2860
P304
P356
10.1111/J.1600-6143.2011.03976.X
P407
P577
2012-02-15T00:00:00Z